| scholarly article | Q13442814 |
| P50 | author | Anastasios Sofiadis | Q37384602 |
| Andrii Dinets | Q37384625 | ||
| P2093 | author name string | C Larsson | |
| D Xu | |||
| J Cao | |||
| T Liu | |||
| J Zedenius | |||
| N Wang | |||
| P2860 | cites work | The Hallmarks of Cancer | Q221226 |
| Telomerase modulates Wnt signalling by association with target gene chromatin | Q24310084 | ||
| Telomere measurement by quantitative PCR | Q24529938 | ||
| Human telomerase and its regulation | Q24533247 | ||
| Clinical, genetic, and immunohistochemical characterization of 70 Ukrainian adult cases with post-Chornobyl papillary thyroid carcinoma | Q24616408 | ||
| Highly prevalent TERT promoter mutations in aggressive thyroid cancers | Q27852353 | ||
| Highly recurrent TERT promoter mutations in human melanoma | Q29614798 | ||
| A survey of telomerase activity in human cancer | Q29614858 | ||
| TERT promoter mutations in familial and sporadic melanoma | Q29614920 | ||
| Regulation of the human catalytic subunit of telomerase (hTERT). | Q34180715 | ||
| Telomerase contributes to tumorigenesis by a telomere length-independent mechanism | Q34188701 | ||
| Molecular pathogenesis and mechanisms of thyroid cancer | Q34329018 | ||
| Telomeres and telomerase: the path from maize, Tetrahymena and yeast to human cancer and aging | Q34571596 | ||
| Telomerase activity in benign and malignant human thyroid tissues | Q36292966 | ||
| TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal | Q36762656 | ||
| Aging phenotypes in cultured normal human mammary epithelial cells are correlated with decreased telomerase activity independent of telomere length | Q36901197 | ||
| Telomerase and the endocrine system | Q37859251 | ||
| Telomerase reverse transcriptase promotes epithelial-mesenchymal transition and stem cell-like traits in cancer cells | Q39263985 | ||
| Differentiating alternative splice variant patterns of human telomerase reverse transcriptase in thyroid neoplasms | Q40116749 | ||
| Telomere length and human telomerase reverse transcriptase expression as markers for progression and prognosis of colorectal carcinoma | Q47605502 | ||
| Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma. | Q47704838 | ||
| A PCR-based expression signature of malignancy in follicular thyroid tumors. | Q51910136 | ||
| Catalytic Subunit of Human Telomerase Reverse Transcriptase Is an Independent Predictor of Survival in Patients Undergoing Curative Resection of Hepatic Colorectal Metastases: A Multicenter Analysis | Q60629744 | ||
| Thyroid carcinomas that express telomerase follow a more aggressive clinical course in children and adolescents | Q74177166 | ||
| TERT regulates cell survival independent of telomerase enzymatic activity | Q74355604 | ||
| Telomerase expression predicts unfavorable outcome in osteosarcoma | Q80558291 | ||
| Telomerase activity in "suspicious" thyroid cytology | Q81069306 | ||
| Telomerase activity in fine needle aspiration biopsy samples: application to diagnosis of human thyroid carcinoma | Q83114530 | ||
| P433 | issue | 42 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 4978-4984 | |
| P577 | publication date | 2013-10-21 | |
| P1433 | published in | Oncogene | Q1568657 |
| P1476 | title | The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas | |
| P478 | volume | 33 |
| Q38838144 | Altered TERT promoter and other genomic regulatory elements: occurrence and impact |
| Q35441872 | Association of TERT promoter mutation 1,295,228 C>T with BRAF V600E mutation, older patient age, and distant metastasis in anaplastic thyroid cancer |
| Q36221232 | Association of telomerase reverse transcriptase promoter mutations with clinicopathological features and prognosis of thyroid cancer: a meta-analysis |
| Q27853042 | BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence |
| Q92904521 | BRAF and TERT mutations in papillary thyroid cancer patients of Latino ancestry |
| Q37109755 | BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients |
| Q26738705 | Cancer-Specific Telomerase Reverse Transcriptase (TERT) Promoter Mutations: Biological and Clinical Implications |
| Q55026989 | Classic Architecture with Multicentricity and Local Recurrence, and Absence of TERT Promoter Mutations are Correlates of BRAF (V600E) Harboring Pediatric Papillary Thyroid Carcinomas. |
| Q35901458 | Clinical Characteristics and Prognostic Significance of TERT Promoter Mutations in Cancer: A Cohort Study and a Meta-Analysis |
| Q90334968 | Clinical Routine TERT Promoter Mutational Screening of Follicular Thyroid Tumors of Uncertain Malignant Potential (FT-UMPs): A Useful Predictor of Metastatic Disease |
| Q36560914 | Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation |
| Q37626548 | Clinicopathological characteristics of TERT promoter mutation and telomere length in hepatocellular carcinoma |
| Q38687220 | Clinicopathological significance of TERT promoter mutation in papillary thyroid carcinomas: a systematic review and meta-analysis |
| Q91095415 | Clonal evolution analysis of paired anaplastic and well-differentiated thyroid carcinomas reveals shared common ancestor |
| Q55436824 | Co-existence of BRAFV600E and TERT promoter mutations in papillary thyroid carcinoma is associated with tumor aggressiveness, but not with lymph node metastasis. |
| Q27853057 | Diagnostic and prognostic TERT promoter mutations in thyroid fine-needle aspiration biopsy. |
| Q92618724 | Different correlations between tumor size and cancer-related gene profiles according to histologic type of salivary gland tumor |
| Q92664567 | Diverse regulatory manners of human telomerase reverse transcriptase |
| Q26778154 | ENDOCRINE TUMOURS: Genetic predictors of thyroid cancer outcome |
| Q48651339 | Follicular cell-derived thyroid cancer. |
| Q90699489 | Follow-up of differentiated thyroid cancer - what should (and what should not) be done |
| Q52911465 | Frequent BRAF V600E and Absence of TERT Promoter Mutations Characterize Sporadic Pediatric Papillary Thyroid Carcinomas in Japan. |
| Q91289304 | GABPA inhibits invasion/metastasis in papillary thyroid carcinoma by regulating DICER1 expression |
| Q91698505 | GABPA is a master regulator of luminal identity and restrains aggressive diseases in bladder cancer |
| Q90267289 | GABPA-dependent down-regulation of DICER1 in follicular thyroid tumours |
| Q95271447 | GADD45B Transcript Is a Prognostic Marker in Papillary Thyroid Carcinoma Patients Treated With Total Thyroidectomy and Radioiodine Therapy |
| Q37225274 | Genetic and epigenetic background and protein expression profiles in relation to telomerase activation in medullary thyroid carcinoma |
| Q48291446 | Genetic landscape of papillary thyroid carcinoma in the Chinese population. |
| Q36618604 | Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. |
| Q33591794 | Hobnail variant of papillary thyroid carcinoma: molecular profiling and comparison to classical papillary thyroid carcinoma, poorly differentiated thyroid carcinoma and anaplastic thyroid carcinoma |
| Q49721248 | Identification of Single Nucleotide Non-coding Driver Mutations in Cancer |
| Q51415479 | In Japanese patients with papillary thyroid carcinoma, TERT promoter mutation is associated with poor prognosis, in contrast to BRAF V600E mutation. |
| Q91055054 | Incremental utility of expanded mutation panel when used in combination with microRNA classification in indeterminate thyroid nodules |
| Q39627113 | Interaction of Age at Diagnosis with Transcriptional Profiling in Papillary Thyroid Cancer |
| Q47702648 | Low frequency of TERT promoter mutations in a series of well-differentiated follicular-patterned thyroid neoplasms |
| Q91723523 | Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players |
| Q94948450 | Molecular Profile of Locally Aggressive Well Differentiated Thyroid Cancers |
| Q45143637 | Molecular alterations in endometrial and ovarian clear cell carcinomas: clinical impacts of telomerase reverse transcriptase promoter mutation. |
| Q48088782 | Molecular alterations of coexisting thyroid papillary carcinoma and anaplastic carcinoma: identification of TERT mutation as an independent risk factor for transformation |
| Q34160828 | Molecular approaches to thyroid cancer diagnosis |
| Q47295202 | Molecular pathology of thyroid tumours of follicular cells: a review of genetic alterations and their clinicopathological relevance. |
| Q98243177 | Multiplatform molecular test performance in indeterminate thyroid nodules |
| Q26782322 | Mutation Profile of Well-Differentiated Thyroid Cancer in Asians |
| Q41143039 | Mutation of the TERT promoter leads to poor prognosis of patients with non-small cell lung cancer |
| Q35941457 | Mutation rate estimation for 15 autosomal STR loci in a large population from Mainland China |
| Q52956152 | Mutations in TERT promoter and FGFR3 and telomere length in bladder cancer. |
| Q42014310 | NGS based identification of mutational hotspots for targeted therapy in anaplastic thyroid carcinoma |
| Q58550783 | Not the same thing: metastatic PTCs have a different background than ATCs |
| Q41381572 | Oncogenesis of Thyroid Cancer |
| Q90318108 | Pathogenic TERT promoter variants in telomere diseases |
| Q49442455 | Preclinical and clinical implications of TERT promoter mutation in glioblastoma multiforme |
| Q49803880 | Presence of TERT Promoter Mutations is a Secondary Event and Associates with Elongated Telomere Length in Myxoid Liposarcomas |
| Q38416278 | Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients. |
| Q64084348 | Promoter Hypomethylation as Recurrence Predictive Marker in Well-Differentiated Thyroid Carcinomas |
| Q43274590 | Sensitive droplet digital PCR method for detection of TERT promoter mutations in cell free DNA from patients with metastatic melanoma |
| Q92596277 | Spectrum of TERT promoter mutations and mechanisms of activation in thyroid cancer |
| Q39676067 | TERT Core Promotor Mutations in Early-Onset Bladder Cancer |
| Q54522397 | TERT Promoter Hypermethylation in Gastrointestinal Cancer: A Potential Stool Biomarker. |
| Q48197559 | TERT Promoter Mutation and Telomere Length in Salivary Gland Tumors. |
| Q37097535 | TERT Promoter Mutations and Tumor Persistence/Recurrence in Papillary Thyroid Cancer. |
| Q38744769 | TERT Promoter Mutations in Thyroid Cancer |
| Q37408393 | TERT promoter Mutation and Its Association with Clinicopathological Features and Prognosis of Papillary Thyroid Cancer: A Meta-analysis |
| Q88962020 | TERT promoter mutational screening as a tool to predict malignant behaviour in follicular thyroid tumours-three examples from the clinical routine |
| Q35151119 | TERT promoter mutations and TERT mRNA but not FGFR3 mutations are urinary biomarkers in Han Chinese patients with urothelial bladder cancer |
| Q34654382 | TERT promoter mutations and gene amplification: promoting TERT expression in Merkel cell carcinoma |
| Q35833084 | TERT promoter mutations and telomere length in adult malignant gliomas and recurrences. |
| Q33682388 | TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer |
| Q34313648 | TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas |
| Q35068013 | TERT promoter mutations are associated with distant metastases in upper tract urothelial carcinomas and serve as urinary biomarkers detected by a sensitive castPCR |
| Q36287405 | TERT promoter mutations are frequent and show association with MED12 mutations in phyllodes tumors of the breast |
| Q54314475 | TERT promoter mutations in clear cell renal cell carcinoma. |
| Q33688439 | TERT promoter mutations in renal cell carcinomas and upper tract urothelial carcinomas |
| Q26770808 | TERT promoter mutations in thyroid cancer |
| Q89287810 | TERTp mutation is associated with a shorter progression free survival in patients with aggressive histology subtypes of follicular-cell derived thyroid carcinoma |
| Q38232447 | Telomerase promoter mutations in cancer: an emerging molecular biomarker? |
| Q47266315 | Telomerase reverse transcriptase mutations are independent predictor of disease-free survival in Middle Eastern papillary thyroid cancer. |
| Q91028354 | Telomerase reverse transcriptase promoter mutations in cancers derived from multiple organ sites among middle eastern population |
| Q37317414 | Telomerase reverse transcriptase promoter mutations in hepatitis B virus-associated hepatocellular carcinoma. |
| Q54374929 | Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma. |
| Q34396480 | Telomerase-dependent and independent telomere maintenance and its clinical implications in medullary thyroid carcinoma |
| Q55443450 | Telomere Maintenance Mechanisms in Cancer. |
| Q91379882 | Telomere length, telomerase reverse transcriptase promoter mutations, and melanoma risk |
| Q34784471 | Telomere-regulating genes and the telomere interactome in familial cancers. |
| Q92812744 | The Long Non-Coding RNA Prader Willi/Angelman Region RNA5 (PAR5) Is Downregulated in Anaplastic Thyroid Carcinomas Where It Acts as a Tumor Suppressor by Reducing EZH2 Activity |
| Q93190093 | The Role of Proton Transfer on Mutations |
| Q90596932 | The Solo Play of TERT Promoter Mutations |
| Q33618591 | The TERT promoter mutation incidence is modified by germline TERT rs2736098 and rs2736100 polymorphisms in hepatocellular carcinoma |
| Q33709979 | The activating TERT promoter mutation C228T is recurrent in subsets of adrenal tumors |
| Q28392404 | The association between the TERT rs2736100 AC genotype and reduced risk of upper tract urothelial carcinomas in a Han Chinese population |
| Q37295512 | The genetic difference between Western and Chinese urothelial cell carcinomas: infrequent FGFR3 mutation in Han Chinese patients |
| Q42318053 | Thyroglobulin in Metastatic Thyroid Cancer: Culprit or Red Herring? |
| Q38695744 | Thyrospheres from B-CPAP Cell Line with BRAF and TERT Promoter Mutations have Different Functional and Molecular Features than Parental Cells |
| Q26739925 | Transcription Regulation of the Human Telomerase Reverse Transcriptase (hTERT) Gene |
| Q90917856 | Transcriptome analysis of papillary thyroid cancer harboring telomerase reverse transcriptase promoter mutation |
| Q47185839 | Ultrasound and clinicopathological features of papillary thyroid carcinomas with BRAF and TERT promoter mutations |
| Q38760235 | Understanding TERT Promoter Mutations: A Common Path to Immortality. |
| Q59806817 | Unexpected Routes of the Mutagenic Tautomerization of the T Nucleobase in the Classical A·T DNA Base Pairs: A QM/QTAIM Comprehensive View |
| Q34152070 | Update on anaplastic thyroid carcinoma: morphological, molecular, and genetic features of the most aggressive thyroid cancer |
| Q89184014 | [Genetics of thyroid nodules and thyroid carcinoma] |
Search more.